Established in 2014, Cann Group was the recipient of the first licence issued by the Australian Government’s Office of Drug Control (ODC) in February 2017. This Licence enables Cann to cultivate medicinal cannabis and conduct research on the use of cannabis for medicinal purposes. In addition, in March 2017, Cann Group was issued Australia’s first Medicinal Cannabis Cultivation Licence, allowing it to produce Australian-grown material that can be prescribed for patient use. The company was incorporated early in 2017 to coincide with its licensing and permit.
Cann’s Board and management have extensive experience in the agriculture, agronomic and health research sectors and in developing and commercialising agricultural technology.
Cann has established R&D and cultivation facilities in Australia and is pursuing a fully-integrated business model with collaboration agreements, resources and capabilities that will enable it to establish a leading position in plant genetics, breeding, cultivation, production, manufacturing, and clinical evaluation to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions.
Cann’s vision is to be a leading developer and supplier of cannabis, cannabis resin and medicinal cannabis products for the benefit of Australians.